至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Production of an active anti-CD20-hIL-2 immunocytokine in Nicotiana benthamiana.

Plant Biotechnol. J.. 2016-12; 
MarusicCarla,NovelliFlavia,SalzanoAnna M,ScaloniAndrea,BenvenutoEugenio,PioliClaudio,DoniniMarc
Products/Services Used Details Operation
Custom Vector Construction Anti-CD20 2B8-Fc-hIL2 was synthetically constructed (GenScript) based on the v gene sequences of the murine 2B8 (US Patent No. 5,736,137). .. All synthetic genes were codonoptimized for expression in N. benthamiana using the OptimumGeneTM algorithm (GenScript, Piscataway, NJ) Get A Quote

摘要

Anti-CD20 murine or chimeric antibodies (Abs) have been used to treat non-Hodgkin lymphomas (NHLs) and other diseases characterized by overactive or dysfunctional B cells. Anti-CD20 Abs demonstrated to be effective in inducing regression of B-cell lymphomas, although in many cases patients relapse following treatment. A promising approach to improve the outcome of mAb therapy is the use of anti-CD20 antibodies to deliver cytokines to the tumour microenvironment. In particular, IL-2-based immunocytokines have shown enhanced antitumour activity in several preclinical studies. Here, we report on the engineering of an anti-CD20-human interleukin-2 (hIL-2) immunocytokine (2B8-Fc-hIL2) based on the C2B8 mAb (Ri... More

关键词

antibody-dependent cell-mediated cytotoxicity,human interleukin-2,immunocytokine,molecular farming,non-Hodgkin lymph